Home > Riviste > Italian Journal of Dermatology and Venereology > Fascicoli precedenti > Italian Journal of Dermatology and Venereology 2022 August;157(4) > Italian Journal of Dermatology and Venereology 2022 August;157(4):355-62

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   Free accessfree

Italian Journal of Dermatology and Venereology 2022 August;157(4):355-62

DOI: 10.23736/S2784-8671.22.07275-9

Copyright © 2022 EDIZIONI MINERVA MEDICA

lingua: Inglese

PD-1 and PD-L1 expression in mycosis fungoides and Sézary Syndrome

Alessandro PILERI 1, 2 , Valentina TABANELLI 3, Fabio FULIGNI 4, Claudio AGOSTINELLI 5, 6, Alba GUGLIELMO 1, 2, Elena SABATTINI 5, Vieri GRANDI 7, Stefano A. PILERI 3, Nicola PIMPINELLI 7

1 Unit of Dermatology, IRCCS Sant’Orsola Polyclinic, Bologna, Italy; 2 Unit of Dermatology, Department of Experimental Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 3 Division of Hematopathology, IRCCS European Institute of Oncology (IEO), Milan, Italy; 4 Department of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada; 5 Unit of Hematopathology, Department of Experimental Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; 6 Unit of Hematopathology, IRCCS Sant’Orsola Polyclinic, Bologna, Italy; 7 Division of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy



BACKGROUND: The mechanisms involved in mycosis fungoides, and Sezary Syndrome progression are largely unknown. Over the last decade the interest in immune system contrast of neoplasm has grown owing to the introduction of immunotherapy. PD-1 and its ligand (PD-L1) are the target of several immunotherapy treatment. In the literature reports on the expression of PD-1 and PD-L1 have provided contrasting results.
METHODS: In our analysis we investigated PD-1 expression in neoplastic cells and in tumor infiltrating lymphocytes (TILs) as well as PD-L1 expression in tumor cells and in tumor associated macrophages (TAMs). PD-L1 and PD-1 positive cells were counted in 5 high-power fields (HPF) and scored as the average number of positive neoplastic cells/TILs/TAMs per HPF.
RESULTS: From databases of two institutions (Bologna and Florence) thirty-five patients corresponding to 43 biopsies were retrieved. In seven instances sequential biopsies were present. No statistically significant expression was observed comparing early to advanced stages by analysing PD-1 by tumor cells and TILs and of PD-L1 by tumor cells and TAMs.
CONCLUSIONS: Our results corroborate that PD-1 and PD-L1 expression is not stage-dependent in mycosis fungoides and Sezary syndrome. However, PD-1 and PD-L1 expression in affected patients provides a rationale to schedule anti PD-1/PD-L1 drugs.


KEY WORDS: Mycosis fungoides; Sezary Syndrome; Immunotherapy

inizio pagina